论文部分内容阅读
目的:比较促红素低剂量与常规剂量治疗恶性肿瘤贫血的疗效及不良反应。方法:将符合条件的44例恶性肿瘤贫血患者随机分成2组,分别为促红素低剂量组(2万U/周)和常规剂量组(4万U/周),共治疗8周,每2周进行一次疗效观察。结果:(1)2组患者的血红蛋白值和血细胞比容值均明显升高,治疗4~6周后与治疗前相比差异有统计学意义(P<0.05或P<0.01)。其中低剂量组在治疗6周后显效,常规剂量组在治疗4周后显效;(2)低剂量组的8周有效率、8周血红蛋白值和血细胞比容值均低于常规剂量组(P<0.05或P<0.01);(3)2组的不良反应发生率和输血需求率差异无显著性(P>0.05)。结论:促红素常规剂量治疗恶性肿瘤贫血的疗效优于低剂量,两者不良反应差异无显著性。
Objective: To compare the efficacy and adverse reactions of erythropoietin low dose and conventional dose in treating malignant anemia. Methods: Forty-four patients with malignant tumor anemia were randomly divided into two groups: low-dose erythorhod (20,000 U / week) and conventional dose group (40,000 U / week) 2 weeks for a curative effect observation. Results: (1) The hemoglobin and hematocrit of the two groups were significantly higher than those before treatment (P <0.05 or P <0.01) after 4 to 6 weeks of treatment. The low-dose group was effective after 6 weeks of treatment, and the conventional dose group was effective after 4 weeks of treatment. (2) The 8-week efficiency, 8-week hemoglobin and hematocrit of the low-dose group were lower than those of the conventional dose group <0.05 or P <0.01). (3) There was no significant difference in incidence of adverse reactions and blood transfusion requirements between the two groups (P> 0.05). Conclusion: The efficacy of routine dose of erythropoietin in the treatment of malignant anemia is better than that of low dose, with no significant difference between the two groups.